New protective compound designed to shield healthy tissue from radiation

A recently developed radioprotective compound has shown potential to protect healthy tissue from ionizing radiation associated with cancer treatment.

BIO 300 was created by Minneapolis-based Humanetics Corporation and demonstrated promising ability as a therapeutic measure against harm caused by radiation from sources like cancer radiotherapy.

Humanetics said promising preclinical results have led to a clinical trial to evaluate the ability of BIO 300 to lessen the normal tissue side effects from chemotherapy and radiation associated with lung cancer treatment. This trial is scheduled to begin in the second quarter of 2015, according to a company press release.

Around the web

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.